Avalo Therapeutics (AVTX) Debt/Equity Ratio: History & Chart

Avalo Therapeutics, Inc.(AVTX)

Biotechnology · Wayne, PA

$14.43-0.17 (-1.16%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

Wayne, PA

33 employees

www.avalotx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Garry A. Neil

View full financials

AVTX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.00

DEBT TO EQUITY RATIO AVG TTM

0.02

DEBT TO EQUITY RATIO AVG 3Y

0.01

DEBT TO EQUITY RATIO AVG 5Y

0.01

DEBT TO EQUITY RATIO AVG 10Y

0.30

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-96.47%

CURRENT VS 3Y AVG

-94.30%

CURRENT VS 5Y AVG

-96.36%

CURRENT VS 10Y AVG

-99.82%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.14

median of 470 covered companies

CURRENT VS SECTOR MEDIAN

-99.61%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Avalo Therapeutics, Inc. (AVTX)	$758.52M	0.00	0.02	0.01	0.01
Candel Therapeutics, Inc. (CADL)vs ›	$751.75M	0.39	0.12	0.63	0.50
Achieve Life Sciences, Inc. (ACHV)vs ›	$721.69M	N/A	0.58	1.04	0.73
Geron Corporation (GERN)vs ›	$773.03M	0.56	0.77	0.65	0.53
Anteris Technologies Global Corp. (AVR)vs ›	$729.24M	0.01	0.06	0.15	0.44
Design Therapeutics, Inc. (DSGN)vs ›	$765.10M	0.01	0.01	0.01	0.01
AdaptHealth Corp. (AHCO)vs ›	$791.15M	1.50	1.31	1.32	1.45
Attovia Therapeutics, Inc. (ATTO)vs ›	$777.12M	0.04	0.01	0.01	0.01
Cytek Biosciences, Inc. (CTKB)vs ›	$796.81M	0.08	0.06	0.05	0.04
Collegium Pharmaceutical, Inc. (COLL)vs ›	$711.27M	2.75	3.44	3.49	2.78

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Avalo Therapeutics, Inc. (AVTX)

$758.52M

0.00

0.02

0.01

Candel Therapeutics, Inc. (CADL)vs ›

$751.75M

0.39

0.12

0.63

0.50

Achieve Life Sciences, Inc. (ACHV)vs ›

$721.69M

N/A

0.58

1.04

0.73

Geron Corporation (GERN)vs ›

$773.03M

0.56

0.77

0.65

0.53

Anteris Technologies Global Corp. (AVR)vs ›

$729.24M

0.01

0.06

0.15

0.44

Design Therapeutics, Inc. (DSGN)vs ›

$765.10M

0.01

AdaptHealth Corp. (AHCO)vs ›

$791.15M

1.50

1.31

1.32

1.45

Attovia Therapeutics, Inc. (ATTO)vs ›

$777.12M

0.04

0.01

Cytek Biosciences, Inc. (CTKB)vs ›

$796.81M

0.08

0.06

0.05

0.04

Collegium Pharmaceutical, Inc. (COLL)vs ›

$711.27M

2.75

3.44

3.49

2.78

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Avalo Therapeutics, Inc. (AVTX)?

The debt to equity ratio for AVTX stock is 0.00.

Is Avalo Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.00 is 96% below its 5-year average of 0.01, around the middle of its 5-year range (-9.66–5.31).

What is the TTM average debt to equity ratio for Avalo Therapeutics, Inc. (AVTX)?

The TTM average debt to equity ratio for AVTX stock is 0.02.

What is the 3Y average debt to equity ratio for Avalo Therapeutics, Inc. (AVTX)?

The 3Y average debt to equity ratio for AVTX stock is 0.01.

What is the 5Y average debt to equity ratio for Avalo Therapeutics, Inc. (AVTX)?

The 5Y average debt to equity ratio for AVTX stock is 0.01.

What is the 10Y average debt to equity ratio for Avalo Therapeutics, Inc. (AVTX)?

The 10Y average debt to equity ratio for AVTX stock is 0.30.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.00
2026-03-31	0.03
2025-12-31	0.03
2025-09-30	0.01
2025-06-30	0.01
2025-03-31	0.01
2024-12-31	0.00
2024-09-30	0.03
2024-06-30	-0.04
2024-03-31	-0.01
2023-12-31	0.07
2023-09-30	0.04
2023-06-30	-2.10
2023-03-31	-3.24
2022-12-31	-1.83
2022-09-30	-9.66
2022-06-30	-3.23
2022-03-31	5.31
2021-12-31	1.44
2021-09-30	0.81
2021-06-30	0.81
2021-03-31	0.01
2020-12-31	0.02
2020-09-30	0.06
2020-06-30	0.01
2020-03-31	0.00
2019-12-31	0.01
2019-09-30	0.90
2019-06-30	0.93
2019-03-31	0.66
2018-12-31	0.74
2018-09-30	0.79
2018-06-30	0.80
2018-03-31	0.63
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.19
2017-03-31	-3.51
2016-12-31	11.37
2016-09-30	5.44
2016-06-30	0.72
2016-03-31	0.54
2015-12-31	0.43
2015-09-30	-0.19
2015-06-30	-3.03
2015-03-31	-0.25
2014-12-31	-0.27
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.00
2012-12-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.00

2026-03-31

0.03

2025-12-31

0.03

2025-09-30

0.01

2025-06-30

0.01

2025-03-31

0.01

2024-12-31

0.00

2024-09-30

0.03

2024-06-30

-0.04

2024-03-31

-0.01

2023-12-31

0.07

2023-09-30

0.04

2023-06-30

-2.10

2023-03-31

-3.24

2022-12-31

-1.83

2022-09-30

-9.66

2022-06-30

-3.23

2022-03-31

5.31

2021-12-31

1.44

2021-09-30

0.81

2021-06-30

0.81

2021-03-31

0.01

2020-12-31

0.02

2020-09-30

0.06

2020-06-30

0.01

2020-03-31

0.00

2019-12-31

0.01

2019-09-30

0.90

2019-06-30

0.93

2019-03-31

0.66

2018-12-31

0.74

2018-09-30

0.79

2018-06-30

0.80

2018-03-31

0.63

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.19

2017-03-31

-3.51

2016-12-31

11.37

2016-09-30

5.44

2016-06-30

0.72

2016-03-31

0.54

2015-12-31

0.43

2015-09-30

-0.19

2015-06-30

-3.03

2015-03-31

-0.25

2014-12-31

-0.27

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.00

2012-12-31

0.00

Debt to Equity Ratio: 0.00

AVTX Debt to Equity Ratio

AVTX Average Debt to Equity Ratio Chart

AVTX Current vs Average Debt to Equity Ratio Chart

AVTX Debt to Equity Ratio Metrics

AVTX Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

AVTX Debt to Equity Ratio History

Related Metrics